Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks

PURPOSE: The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt signaling pathway as a critical modulator of cell survival. METHODS: The mTOR inhibitor temsirolimus (CCI-779) was combined with chemo-radiotherapy in GBM patients in a dose-escalation Phase I trial. The first 12 patient...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Sarkaria, Jann N., Galanis, Eva, Wu, Wenting, Dietz, Allan B., Kaufmann, Timothy J., Gustafson, Michael P., Brown, Paul D., Uhm, Joon H., Rao, Ravi D., Doyle, Laurence, Giannini, Caterina, Jaeckle, Kurt A., Buckner, Jan C.
Format: Artigo
Sprog:Inglês
Udgivet: 2010
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2982871/
https://ncbi.nlm.nih.gov/pubmed/20921209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1453
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker